Home | Osteogenex Inc. | Kansas City, KS, 66103
OsteoGeneX is developing a first in class bone building small molecule against the validated target Sclerostin. OsteoGeneX possesses both near term accelerated clinical development opportunities, combined with proprietary approaches to developing first-i
